Inclusion Criteria:

- Histologic or cytological diagnosis of NSCLC who failed previous platinum-based and
taxanes chemotherapy.

- No prior radiotherapy on measurable lesion(s).

- Performance status of 0 to 3 on the Zubrod scale. (Reference 1)

- Clinically measurable disease, defined as bidimensionally measurable lesions with
clearly defined margins on x-ray, scan, or physical examination. Lesions serving as
measurable disease must be at least 1 cm by 1 cm, as defined by CT scan, MRI, or
chest x-ray.

- Informed consent from patient.

- Males or females 18 years of age or older.

- If female: childbearing potential either terminated by surgery, radiation, or
menopause, or attenuated by use of an approved contraceptive method (intrauterine
contraceptive device [IUD], birth control pills, or barrier device) during and for
three months after trial.

Exclusion Criteria:

- Active infection (at the discretion of the investigator).

- Inadequate liver function (total bilirubin >1.5 times above normal range); alanine
transaminase (ALT) and aspartate transaminase (AST) greater than 5 times normal.

- Inadequate renal function (creatinine >2.0 mg/dL).

- Breast feeding.

- Second primary malignancy (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin)

- Concomitant myelosuppressive radiotherapy, chemotherapy, hormonal therapy, or
immunotherapy will not be allowed except as for palliative radiation to
non-measurable lesion.